Plasma levels of lipoprotein (a) do not predict progression of human chronic renal failure

No abstract is available for this paper.

• Publication year

  1996

• Venue

  Nephrology Dialysis Transplantation

• Publication date

  1996-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/OXFORDJOURNALS.NDT.A027142
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Interaction of native and oxidized lipoprotein(a) with human mesangial cells and matrix.

  1996cited by this paper
• Effects of lipoprotein(a) on mesangial cell proliferation and viability.

  1996cited by this paper
• Lipoprotein(a) in renal disease.

  1996cited by this paper
• Multicenter study of lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease treated by hemodialysis or continuous ambulatory peritoneal dialysis.

  1995cited by this paper
• Lipoprotein(a) in renal disease: what we have, what we need, what we can forget.

  1995cited by this paper
• Lipoprotein(a): friend or foe?

  1995cited by this paper
• Report on a workshop to develop management recommendations for the prevention of progression in chronic renal disease.

  1995cited by this paper
• Comparison of Lp(a) concentrations and some potential effects in hemodialysis, CAPD, transplantation, and control groups, and review of the literature.

  1995cited by this paper
• Lipoprotein(a) in renal patients: is it a key factor in the high cardiovascular mortality?

  1994cited by this paper
• The Effects of Dietary Protein Restriction and Blood-Pressure Control on the Progression of Chronic Renal Disease

  1994cited by this paper
• Symptomatic antiproteinuric treatment decreases serum lipoprotein (a) concentration in patients with glomerular proteinuria.

  1994cited by this paper
• Apolipoprotein(a) phenotype-associated decrease in lipoprotein(a) plasma concentrations after renal transplantation.

  1994cited by this paper
• Prevention of restenosis after percutaneous transluminal coronary angioplasty by reducing lipoprotein (a) levels with low-density lipoprotein apheresis

  1994cited by this paper
• Effect of sample storage on the measurement of lipoprotein[a], apolipoproteins B and A-IV, total and high density lipoprotein cholesterol and triglycerides.

  1994cited by this paper
• Lipoprotein(a): important risk factor or passing fashion?

  1993cited by this paper
• Lipoprotein metabolism and renal failure.

  1993cited by this paper
• Localization of apolipoprotein(a) and B-100 in various renal diseases.

  1993cited by this paper
• Apolipoprotein-B-containing lipoproteins and the progression of renal insufficiency.

  1993cited by this paper
• Elevated Plasma Lipoprotein(a) in Patients with the Nephrotic Syndrome

  1993cited by this paper
• A prospective study of lipoprotein(a) and the risk of myocardial infarction.

  1993cited by this paper
• Lipoprotein(a) levels in chronic renal disease states, dialysis and transplantation.

  1992cited by this paper
• Decreases in apolipoprotein(a) after renal transplantation: implications for lipoprotein(a) metabolism.

  1992cited by this paper
• Lipoprotein(a). Clinical approach to a unique atherogenic lipoprotein.

  1992cited by this paper
• Natural history of chronic renal failure: a reappraisal.

  1992cited by this paper
• Apo(a) isoforms predict risk for coronary heart disease. A study in six populations.

  1992cited by this paper
• Lipoprotein(a) Is an Independent Risk Factor for Cardiovascular Disease in Hemodialysis Patients

  1992cited by this paper
• Lipids and apolipoproteins change during the progression of chronic renal failure.

  1992cited by this paper
• Increased lipoprotein(a) concentrations in chronic renal failure.

  1992cited by this paper
• Lipoprotein(a). A genetic risk factor for premature coronary heart disease.

  1992cited by this paper
• Chronic renal failure: pathophysiology.

  1991cited by this paper
• Lipoprotein (a) and coronary heart disease risk: a nested case-control study of the Helsinki Heart Study participants.

  1991cited by this paper
• Lipid and apolipoprotein profiles of uremic dyslipoproteinemia--relation to renal function and dialysis.

  1991cited by this paper
• Progression of chronic renal failure in man.

  1990cited by this paper
• The mysteries of lipoprotein(a).

  1989cited by this paper
• Progression of renal disease.

  1989cited by this paper
• A potential basis for the thrombotic risks associated with lipoprotein(a)

  1989cited by this paper
• Tissue distribution of [3H]cholesteryl linoleyl ether-labeled human Lp(a) in different rat organs.

  1988cited by this paper
• Lipoproteins and apolipoproteins during the progression of chronic renal disease.

  1988cited by this paper
• Lp(a) lipoprotein in patients with chronic renal failure treated by hemodialysis.

  1987cited by this paper
• Comparison of Several Atherogenicity Indices by the Analysis of Serum Lipoprotein Composition in Patients with Chronic Renal Failure with or without Haemodialysis, and in Renal Transplant Patients

  1985cited by this paper
• Determination of glomerular filtration rate in advanced renal insufficiency.

  1978cited by this paper

• The role of lipoprotein(a) in progression of renal disease: Causality or reverse causality?

  2016cites this paper
• Lipoprotein(a) in Chronic Renal Failure

  2009cites this paper
• Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative

  2004cites this paper
• A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease.

  2003cites this paper
• Antiproteinuric effect of niceritrol, a nicotinic acid derivative, in chronic renal disease with hyperlipidemia: a randomized trial.

  2003cites this paper
• Plasma lipids and risk of developing renal dysfunction: the atherosclerosis risk in communities study.

  2000cites this paper
• Lipoprotein abnormalities as a risk factor for progressive nondiabetic renal disease.

  1999cites this paper
• Lipoprotein(a) stimulates growth of human mesangial cells and induces activation of phospholipase C via pertussis toxin-sensitive G proteins.

  1999cites this paper
• Dyslipidaemia and the progression of renal disease in chronic renal failure patients.

  1999cites this paper
• Homocysteine, lipoprotein(a) and fibrinogen: metabolic risk factors for cardiovascular complications of chronic renal disease

  1998cites this paper